Efficient Culturing and Genetic Manipulation of Human Pluripotent Stem Cells

Robert T. Schinzel1,2,3,4, Tim Ahfeldt1,2,3, Frank H. Lau2, Youn-Kyoung Lee1,2,3, Alicia Cowley1,2,5, Tony Shen1,2,5, Derek Peters1,2,3, David H. Lum6,7, Chad A. Cowan1,2,3*

1 Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, United States of America, 2 Center for Regenerative Medicine, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 3 Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 4 Institut für Biologie - Mikrobiologie, Fachbereich Biologie, Chemie, Pharmazie, Freie Universität Berlin, Berlin, Germany, 5 Harvard College, Harvard University, Cambridge, Massachusetts, United States of America, 6 Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States of America, 7 Department of Oncological Sciences, University of Utah, Salt Lake City, Utah, United States of America

Abstract

Human pluripotent stem cells (hPSC) hold great promise as models for understanding disease and as a source of cells for transplantation therapies. However, the lack of simple, robust and efficient culture methods remains a significant obstacle for realizing the utility of hPSCs. Here we describe a platform for the culture of hPSCs that 1) allows for dissociation and replating of single cells, 2) significantly increases viability and replating efficiency, 3) improves freeze/thaw viability, 4) improves cloning efficiency, and 5) colony size variation. When combined with standard methodologies for genetic manipulation, we found that the enhanced culture platform allowed for lentiviral transduction rates of up to 95% and electroporation efficiencies of up to 25%, with a significant increase in the total number of antibiotic-selected colonies for screening for homologous recombination. We further demonstrated the utility of the enhanced culture platform by successfully targeting the ISL1 locus. We conclude that many of the difficulties associated with culturing and genetic manipulation of hPSCs can be addressed with optimized culture conditions, and we suggest that the use of the enhanced culture platform could greatly improve the ease of handling and general utility of hPSCs.

Introduction

Since the derivation of human embryonic stem cells [1], their growth and maintenance in culture have remained challenging. When compared to mouse pluripotent stem cells (mPSCs), the human counterparts (hPSCs) are less robust, more prone to spontaneous differentiation, difficult to culture as single cells, and less amenable to genetic manipulation. With the generation of human induced pluripotent stem cells [2–4], there has been increased interest in the use of hPSCs for a variety of applications. Recently, the introduction of defined media conditions, feeder-free culture systems, and chemicals to facilitate survival of hPSCs as single-cells when passaging hPSCs. This culture platform also increased the viability of hPSCS after freezing and thawing. Importantly, the ECP yielded higher clonogenic efficiency, increased transduction by lentiviral vectors, and improved electroporation efficiencies of hPSCs. Finally, we were readily able to perform homologous recombination using the ECP. Thus, the use of the ECP for growth, maintenance, and manipulation of hPSCs provides a robust and efficient culture methodology that promises to improve the utility of hPSCs.

Results and Discussion

The ECP was the combination of a feeder free culture system utilizing Geltrex [5], TeSR defined media [7], Accutase [8] to dissociate and detach cells and Rock-Inhibitor (Y-27632) [6] to stabilize the subsequent intermediate single cell state. This culture platform was extensively evaluated and compared to the standard culture platform (SCP) of hPSCs in feeder free conditions, consisting of a combination of Geltrex, TeSR and Disparse.

We used a combination of recently published hPSC culture protocols and their further optimization to develop a protocol that we term the enhanced culture platform (ECP). We extensively evaluated this platform and compared it to one of the more widely used culture method, here termed the standard culture platform (SCP). We developed multiple lines of evidence that culturing hPSCs using the ECP significantly facilitates their handling and genetic manipulation. Use of the ECP maintained the pluripotency and genetic integrity of hPSCs over long-term culturing and passaging. The ECP improved replating efficiencies and viability of single-cells when passaging hPSCs. This culture platform also increased the viability of hPSCS after freezing and thawing. Importantly, the ECP yielded higher clonogenic efficiency, increased transduction by lentiviral vectors, and improved electroporation efficiencies of hPSCs. Finally, we were readily able to perform homologous recombination using the ECP. Thus, the use of the ECP for growth, maintenance, and manipulation of hPSCs provides a robust and efficient culture methodology that promises to improve the utility of hPSCs.
cytoplasm ratio, and prominent nucleoli. We further evaluated the cells immunohistochemically for markers of pluripotency including OCT4, SOX2, NANOG, and TRA-1-91 (Figure S1A) and found them to be positive for each of the markers. We also confirmed high expression of two master regulators of pluripotency, OCT4 and NANOG, in cells grown using the ECP by quantitative reverse transcription followed by polymerase chain reaction (qRT-PCR) amplification (Figure S1B). We also found that cells of both lines grown using the ECP for more than 15 passages formed teratomas comprising all three embryonic germ layers (Figure S1C) and remained karyotypically normal (Figure S1D).

We next compared the ECP to a well-established culture methodology (SCP) with respect to the ease of handling and maintaining hPSCs in culture. We first determined the percentage of cells reattaching after passage (often referred to as the replating efficiency) using three human embryonic stem cell (hESC) lines of cells reattaching after passage (often referred to as the replating, freeze/thaw, and cloning efficiency of hPSCs, most necessary to set up experiments, as well as reduce the total time in culture over three passages (Figure 1E). We quantified this observation by measuring TRA-1-60 via flow cytometry using limiting dilution (Figure 1C). We found that an average of 4% of plated single cells grown in SCP were able to form clonogenic colonies in comparison to almost 70% grown using the ECP (p = 0.002). As the Rho Associated Kinase (ROCK) Inhibitor (Y-27632) has been previously shown to stabilize the hESC single-cell state [6,11] and is a component of the ECP, a series of experiments were performed to determine the effect of ROCK-Inhibitor in the ECP (Figure S2). While inclusion of ROCK-Inhibitor improved the replating, freeze/thaw, and cloning efficiency of hPSCs, most of the improvement observed with the ECP appeared to be due to the combination of the newly introduced culture techniques rather than the addition of the chemical.

With routine use of the ECP, we made two additional observations. First, dissociation of hPSCs to single cells resulted in more uniform colony sizes. We quantified the colony size distribution by measuring the surface area of 150 colonies three days after passage with either the ECP or the SCP and found a reduction in variability with the ECP (Figure 1D). Second, we observed an increase in the proportion of Tra-1-60 positive cells in culture over three passages (Figure 1E). We quantified this observation by measuring TRA-1-60 via flow cytometry using two hPSC lines that had a relatively high percentage of TRA-1-60 negative cells admixed in culture (42% in HUES1 and 47% in BJ RiPSC). After repeated passaging using the SCP, both hPSC lines showed a marked decrease in the amount of TRA1-60-positive cells [HUES1: 58% in passage 0 (p0) to 40% in passage 3 (p3); BJ RiPSC: 53% in p0 to 12% in p3]. In contrast, hPSCs cultured using the ECP increased the percentage of TRA-1-60-positive cells over time (HUES1: 58% in p0 to 66% in p3; BJ RiPSC: 53% in p0 to 58% in p5). As hPSCs are known to fluctuate in their expression of cell surface markers such as TRA-1-60, this observation may not correspond to an increase in the number of pluripotent cells when cultured with the ECP. In order to determine if the ECP does in fact reduce the proportion of non-pluripotent cells over time additional markers of pluripotency would need to be assessed over a much longer period of time in culture (i.e. 10 passages or more). The increased proportion of TRA-1-60 positive hPSCs together with the reduced colony size variation, may further reduce variability and improve standardization and reproducibility of experiments with hPSCs.

We next sought to evaluate the ECP using two standard methods of genetic manipulation, lentiviral transduction and gene targeting. Lentiviral transduction has been previously reported in hPSCs using ultra-concentrated virus [12], although the reported efficiency in hPSCs remained relatively low (70%–80%) as compared to several other cell types in which transduction efficiencies of 100% can be routinely achieved without ultra-concentrating the virus. Upon transduction of hPSCs grown using the SCP with lentiviral particles designed to constitutively express green fluorescent protein (LV-GFP), GFP-positive cells were found predominantly at the borders of hPSC colonies. In contrast, hPSCs grown in the ECP and subsequently transduced with LV-GFP displayed GFP-positive cells throughout the hPSC colonies (Figure 2A). To quantify the overall efficiency of lentiviral transduction, four hPSC lines grown with either the SCP or the ECP were transduced with LV-GFP using a range of viral particle concentrations, and the percentage of GFP-positive cells was evaluated via flow cytometry (Figure 2B). A significant increase (p = 0.03) in transduction efficiency was observed in hPSCs grown with the ECP (96%) as compared to cells grown with the SCP (54%). In all of the four hPSC lines tested, the transduction efficiencies exceeded 95% with the use of ECP and without the need for ultra-concentration of the virus. The introduction of overexpression and knockdown constructs via lentivirus with greater than 95% efficiency should allow for the routine establishment of hPSC populations that homogeneously express the desired factors without the need for selection strategies.

Finally, we investigated the utility of the ECP for the delivery of plasmids into hPSCs via electroporation for homologous recombination (HR). We first determined the viability of cells electroporated using either the ECP or the SCP and found a significantly increased (p = 0.002) viability of the cells electroporated with the ECP, with an average of 69% surviving the procedure (Figure 2D top). Additionally, the overall percentage of cells that transiently expressed GFP from an electroporated plasmid significantly improved (p = 0.004) from an average of 7.4% (SCP) to 20% (ECP) (Figure 2D middle), thus allowing for a more than 20-fold increase of the total number of viable GFP-positive cells from 0.64% to 13.91% of the initial number of cells. We then attempted to duplicate the previously reported targeting by HR of the ISL1 locus [13]. After a single electroporation of 1 x 10^6 cells, 3,320 colonies of HUES9 cells and 2,750 colonies of BJ RiPSC cells were obtained after antibiotic selection (Figure 2F). We evaluated 85 of the BJ RiPSC colonies for HR via long-range PCR and found one successful event (Figure 2G). The efficiency of HR at this locus with the ECP (1.17%) was comparable to what was previously reported (1.42%). Thus, the recombination frequency at the locus does not appear to change with alteration of culture conditions, but use of the ECP allows for highly efficient target construct delivery and, given the increase in the number of colonies available for screening, should thereby facilitate gene targeting.

In conclusion, the ECP allows for dissociation and replating of single hPSCs, significantly increases viability and replating.
efficiency, and improves freeze/thaw viability and cloning efficiency of hPSCs. The growth of hPSCs with the ECP also reduced colony size variation and might further reduce the proportion of spontaneously arising non-pluripotent cells. When combined with standard methodologies for genetic manipulation, we found that the enhanced culture platform allowed for lentiviral...
transduction rates of up to 95% and electroporation efficiencies of up to 25%, with a significant increase in the total number of antibiotic-resistant colonies. Thus, the growth, maintenance, and manipulation of hPSCs with the ECP significantly facilitates the ease of utilizing hPSCs and should ultimately facilitate many applications of hPSC research.

Figure 2. Comparing genetic manipulation efficiencies of hPSCs using either the standard (SCP) or the enhanced culture platform (ECP). A) Fluorescence image of Lentiviral transduction with an LV-GFP reporter indicate differences in efficiency and distribution of GFP+ cells (lentivirus copy number $5 \times 10^6$ per 30,000 cells). B) Quantification of lentiviral transduction efficiency via flow cytometry towards the LV-GFP reporter with various lentivirus copy numbers (30,000 cells per setup) in 4 different cell lines (standard error, $p = 0.03$; cell lines: HUES6, HUES9, CF RiPSC and BJ RiPSC). C) Representative flow cytometry plot for HUES6 lentiviral transduction efficiency. D) Average efficiency of an EP-GFP reporter plasmid delivered into the HUES9 line via electroporation. The top bars indicate the amount of cells surviving the procedure, the middle bars the percentage of cells that transiently express GFP measured via flow cytometry, and the bottom bar indicate the total percentage of viable GFP positive cell in regards to the initial cell number ($n = 3$ per platform, standard error). E) Representative flow cytometry plot for HUES9 cells expressing GFP after electroporation. F) The table indicates the amount of colonies available for screening after a single electroporation per $10^6$ cells and subsequent antibiotic selection. G) Of these colonies, 85 were screened for successful gene targeting through homologous recombination via long range PCR. doi:10.1371/journal.pone.0027495.g002
Methods

Ethics statement

All animal procedures were approved by the Massachusetts General Hospital subcommittee on research animal care under animal protocols 2009N000050. Mice were maintained at a barrier facility at the Centre for Regenerative Medicine, Massachusetts General Hospital under a 12 hr light/12 hr dark cycle at constant temperature (22°C) with free access to food and water. All efforts were made to minimize suffering.

Maintenance of pluripotent cells

hESCs and hiPSCs were cultured feeder free on Geltrex (Invitrogen) in the chemically defined medium mTESR1 (Stem Cell Technologies). ECP passage: hPSCs were dissociated with 20% Accutase (StemPro®) in PBS for 5–10 minutes at 37°C until the cells could easily be detached with pipetting. Accutase was removed and cells were replated in mTESR1 +0.4 μM ROCK-Inhibitor (Y-27632 Cayman Chemical). ROCK-inhibitor was removed 3–6 h after replating. SCP passage: hPSCs were dissociated by adding Dispase StemCell Tech, 15–20 mg/mL, for 5–10 minutes at 37°C until the cells could easily be detached with pipetting. Accutase was removed and cells were replated in mTESR1 with 0.4 μM ROCK-Inhibitor removed 3–6 h after replating. SCP passage: hPSCs were dissociated by adding Dispase StemCell Tech, 15–20 mg/mL, for 5–10 minutes at 37°C until colony borders started to detach. After repeated washing with DMEM cells were lifted with a cell scraper and the colonies manually disrupted by pipetting several times.

Quantification of the cell viability

To measure the cell viability of the replating efficiency, freeze/thawing and electroporation experiments, the cells were detached with Accutase 2–3 h after being replating. The cells were counted via Hauser Bright-Line Hemacytometer. All counting was done in triplicates.

Immunocytochemistry

The following antibodies were used: Immunostaining- α-SOX2 (Abcam ab15830, 1/200), α-TRA1-81 (Millipore, MAB4381, 1/350), NANOG (Millipore, AB9220, 1/300), OCT3/4 (Abcam, ab19657, 1/300), and Alexa Fluor secondary antibodies (Invitrogen). DAPI stain was used in a 1:5000 dilution to mark cell nuclei. The Images were made either with a Nikon Digital Sight camera mounted to a Nikon Eclipse Ti-S microscope or a Olympus DP72 camera mounted to a Olympus 1X17 microscope. The software packages NIS-Elements and Olympus DP2-BSW were used for image analysis.

RNA extraction, cDNA synthesis, and quantitative RT-PCR

hPSCs were lysed in buffer RLT (Qiagen) with 1% β-Mercaptoethanol and the total RNA purified via the RNeasy mini kit (Qiagen) according to the manufacturer’s instructions. The RNA yield was determined using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies) and 500 ng of total RNA was further converted to cDNA using the Superscript First-Strand Kit (Invitrogen). Quantitative RT-PCR was performed using Quantifast SYBR Green PCR mix (Qiagen) and the Realplex Mastercycler (Eppendorf) with 25 ng of total RNA per reaction. The reaction took place in the presence of OriGene STAR qPCR primer pairs against OCT3/4 (HP206340), NANOG (HP215908) or NESTIN (HP209533).

Teratoma formation

For the teratoma assay, 5×10⁶ cells of either HUES9 or BJ RiPSC were harvested, spun down, and all excess media was removed. In a 20-week old female SCID mouse, the capsule of the right kidney was gently elevated, and one droplet of concentrated cells was inserted under the capsule. At week 6, when adequate tumor size was observed, the tumor was harvested, fixed in 4% Paraformaldehyde, run through an ethanol gradient, and stored in 70% ethanol. Specimens were sectioned and H&E stained. Slides were imaged with a Leica light microscope.

Karyotyping

The cells were submitted to Cell Line Genetics for analysis.

Freeze/thawing

Cells were dissociated either through Accutase digest (ECP) or by Dispase digest (SCP), transferred to mFreSR® (Stem Cell Technologies) and immediately frozen down. After 2–3 weeks in liquid N2 the cells were thawed and plated on Geltrex coated plates in either mTESR1 with 0.4 μM ROCK-Inhibitor (ECP) or mTESR1 (SCP).

Limiting dilution assay

The various cell lines were diluted to a concentration of 0.5cell/96well and two full 96well plates of each setup was prepared. After 7–10 days the cells were fixed with 4% Paraformaldehyde, analyzed via Immunocytochemistry and screened for colonies expressing the pluripotency marker NANOG and OCT3/4.

Flow cytometry analysis

Cells were detached via Accutase digestion, and fixed for 20 minutes at 4°C in 2% Paraformaldehyde. The cells which were subjected immunocytochemistry were initially counted and 1×10⁶ cells were transferred into polypropylene tubes. Staining for the TRA1-60 antigen was performed using an antibody conjugated to alexa fluor 488 (Biolegend, 330613) in 200 μL PBS with 5% FBS. The cells were counted with a FACSCalibur flow cytometer (BD Biosciences) and the data analyzed using the FlowJo software package (Treestar).

 Colony size measurement and variability

Images of random parts of the plate were made either with a Nikon Digital Sight camera mounted to a Nikon Eclipse Ti-S microscope. Three days after replating of single cells, 20 pictures of random areas of the plates were taken and the colony sizes of 150 colonies of each platform were measured with the NIS elements BR 3.10 software.

Production of lentivirus and transduction

We used a third-generation, Tat-free packaging system [14] to produce recombinant lentivirus. The system consists of two packaging plasmids—pMDL, pRev—, the plasmid coding for VSV-G envelope and a vector for constitutive GFP under the CMV promoter [LV-GFP]. All four plasmids were transfected into HEK293FT cells using calcium chlorate as previously reported [15] and the viral supernatant was collected 48 and 72 hours later. The supernatant was filtered through a 0.45 μm filter and the RNA copy numbers per ml determined using the Lenti-X qRT-PCR titration kit. For the transduction hPSCs were dissociated via ECP/SCP and reseeded. Immediately after reattaching, approximately 2 h after the replating, the lentivirus was added to the plate and incubated for 2 hours at 37°C. The viral supernatant was then removed, and cells were washed with DMEM and mTESR1 was added. 48 hours after transduction the cells were collected, fixed and analyzed for GFP expression via flow cytometry.
Electroporation

The Cells were detached with either Accutase or Dispase filtered through a 40 μm cell strainer (BD Falcon) and counted. 40 μg of linearized DNA (EP-GFP) were mixed with 3×10^6 cells in 800 μl PBS. An electric pulse was given in a 0.4 cm cuvette (Bio-Rad Gene Pulser®) with 320 V/200 μF [16]. The cells were recovered and plated on Geltrex coated plates in TeSR and 0.4 μM/ml ROCK-Inhibitor. Viability and efficiency was determined 24 h after electroporation via cell counting and flow cytometry.

Cell-lines

The following human embryonic stem cell lines were used for the experiments: HUES1, HUES2, HUES6, HUES8 and HUES9 all first described in Cowan et al., 2004. The following human induced pluripotent stem cell lines were used for the experiments: BJ RiPSC and CF RiPSC first described by Warren et al., 2010. The HEK293FT cell line used for Lenti-Virus production is distributed Invitrogen (R700-07).

Supporting Information

Figure S1 Long term culture of hPSCs with ECP doesn’t effect pluripotency and Karyotype. HUES9 and BJ RiPSC cells were cultured 15 consecutive times with the ECP and analyzed for pluripotency via A) Immunohistochemistry with the indicated antibodies; nuclei were visualized with DAPI stain, via B) quantitative reverse transcription real time PCR for OCT3/4, NANOG and the negative control NESTIN a neural progenitor cell marker (normalized to HPRT) (n = 3), via C) Teratomaformation of HUES9 hESCs in immunodeficient SCID mice (black arrow top left indicates neural rosette; black arrow top right - pigmented epithelia, grey arrow top right gut-like epithelia; arrow top left indicates neural rosette; black arrow top right - cartilage). Reprogrammed and plated on Geltrex coated plates in TeSR and 0.4 μM/ml ROCK-Inhibitor. Viability and efficiency was determined 24 h after electroporation via cell counting and flow cytometry.

References

1. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, et al. (1998) Embryonic stem cell lines derived from human blastocysts. Science 282: 1145–1147.
2. Park IH, Arora N, Hsu H, Maherali N, Ahfeldt T, et al. (2008) Disease-specific induced pluripotent stem cells. Cell 134: 877–886.
3. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al. (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917–1920.
4. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861–872.
5. Ludwig TE, Bergendahl V, Levenstein ME, Yu J, Probasco MD, et al. (2006) Feeder-independent culture of human embryonic stem cells. Nat Methods 3: 637–646.
6. Watanabe K, Ueno M, Kamiya D, Nishiyama A, Matsumura M, et al. (2007) A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat Biotechnol 25: 681–686.
7. Xu C, Inokuma MS, Denham J, Golds K, Kundra P, et al. (2001) Feeder-free growth of undifferentiated human embryonic stem cells. Nat Biotechnol 19: 971–974.
8. Bajpai R, Lesperance J, Kim M, Terskikh AV (2008) Efficient propagation of single cells Accutase-dissociated human embryonic stem cells. Mol Reprod Dev 75: 818–827.
9. Cowan CA, Klimanskaya I, McMahon J, Atienza J, Witmyer J, et al. (2004) Derivation of embryonic stem-cell lines from human blastocysts. N Engl J Med 350: 1353–1356.
10. Warren I, Manos PD, Ahfeldt T, Leb YH, Li H, et al. (2010) Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7: 618–630.
11. Li X, Krawetz R, Liu S, Meng G, Rancourt DE (2009) ROCK inhibitor improves survival of cryopreserved serum/feeder-free single human embryonic stem cells. Hum Reprod 24: 589–599.
12. Ma Y, Ramezani A, Lewis R, Hawley RG, Thomson JA (2003) High-level sustained transgene expression in human embryonic stem cells using lentiviral vectors. Stem Cells 21: 111–117.
13. Bu L, Jiang X, Martin-Puig S, Caron L, Zhu S, et al. (2009) Human ISL1 heart progenitors generate diverse multipotent cardiovascular cell lineages. Nature 460: 113–117.
14. Tiscornia G, Singer O, Verma IM (2006) Production and purification of lentiviral vectors. Nat Protoc 1: 281–285.
15. al Yacoub N, Romanowska M, Hartounova N, Foerster J (2007) Optimized production and concentration of lentiviral vectors containing large inserts. J Gene Med 9: 579–584.
16. Zwaka TP, Thomson JA (2003) Homologous recombination in human embryonic stem cells. Nat Biotechnol 21: 319–321.